NCT03430063 - A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

October 27, 2021

Study Completion Date

October 27, 2021

Conditions

Advanced Non-Small Cell Lung Carcinoma

Interventions

DRUG

SDREGN2810

Standard dose intravenous (IV) infusion

DRUG

SDREGN2810/ipi

Combination therapy dose IV

DRUG

HDREGN2810

High dose IV

Trial Locations (31)

4040

Regeneron Research Site, Herstal

5530

Regeneron Research Site, Yvoir

8911

Regeneron Research Site, Badalona

11217

Regeneron Research Site, Taipei

16247

Regeneron Research Site, Suwon

22332

Regeneron Research Site, Incheon

28046

Regeneron Research Site, Madrid

29010

Regeneron Research Site, Málaga

35033

Regeneron Research Site, Rennes

44646

Regeneron Research Site, Massillon

44708

Regeneron Research Site, Canton

50009

Regeneron Research Site, Zaragoza

58128

Regeneron Research Site, Jeongnam

81519

Regeneron Research Site, Gdynia

82131

Regeneron Research Site, Gauting

85054

Regeneron Research Site, Phoenix

86021

Regeneron Research Site, Poitiers

86300

Regeneron Research Site, Grudziądz

90033

Regeneron Research Site, Los Angeles

90603

Regeneron Research Site, Whittier

94160

Regeneron Research Site, Saint-Mandé

463707

Regeneron Research Site, Seongnam

04074

Regeneron Research Site, Scarborough

05400

Regeneron Research Site, Otwock

03722

Regeneron Research Site, Seoul

05505

Regeneron Research Site, Seoul

06591

Regeneron Research Site, Seoul

08025

Regeneron Research Site, Barcelona

W1G6AD

Regeneron Research Site, London

M20 4BX

Regeneron Research Site, Manchester

PL68DH

Regeneron Research Site, Plymouth